The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to reverse a prior High Court ruling that granted a patent win to their rival ...

The US government has agreed to pay Pfizer and BioNTech $1.95 billion for 100 million doses of their COVID-19 vaccine if it ...

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said on Wednesday that the U.S. Food and Drug Administration has approved the application of its LP.8.1-adapted monovalent COVID-19 vaccine for use in senior ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...

This real-world study, conducted between September and December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...